MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

Search

Pliant Therapeutics Inc

Отворен

1.48 -3.27

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.47

Максимум

1.57

Ключови измерители

By Trading Economics

Приходи

8M

-50M

EPS

-0.82

Служители

171

EBITDA

7.9M

-48M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+240.91% upside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

6.7M

91M

Предишно отваряне

4.75

Предишно затваряне

1.48

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 23:54 ч. UTC

Горещи акции

Stocks to Watch: Alphabet, Intel, AppFolio

24.04.2025 г., 23:51 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24.04.2025 г., 23:37 ч. UTC

Топ новини

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24.04.2025 г., 23:36 ч. UTC

Топ новини

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24.04.2025 г., 23:13 ч. UTC

Топ новини
Печалби

Google's Earnings Power Holds Up in Global Turbulence -- Update

24.04.2025 г., 23:09 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24.04.2025 г., 22:51 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24.04.2025 г., 22:48 ч. UTC

Топ новини

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24.04.2025 г., 22:47 ч. UTC

Пазарно говорене

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24.04.2025 г., 22:38 ч. UTC

Пазарно говорене
Печалби

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24.04.2025 г., 22:24 ч. UTC

Пазарно говорене
Печалби

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24.04.2025 г., 22:23 ч. UTC

Печалби

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене
Печалби

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24.04.2025 г., 22:09 ч. UTC

Топ новини
Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24.04.2025 г., 22:00 ч. UTC

Пазарно говорене
Печалби

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24.04.2025 г., 21:39 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24.04.2025 г., 21:24 ч. UTC

Топ новини
Печалби

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24.04.2025 г., 21:24 ч. UTC

Топ новини
Печалби

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24.04.2025 г., 21:23 ч. UTC

Топ новини
Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24.04.2025 г., 21:04 ч. UTC

Печалби

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24.04.2025 г., 21:02 ч. UTC

Печалби

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

240.91% нагоре

12-месечна прогноза

Среден 5.25 USD  240.91%

Висок 17 USD

Нисък 1.5 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

13 ratings

2

Купи

11

Задържане

0

Продай

Техническа оценка

By Trading Central

1.46 / 1.58Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.